Parvizi Surgical Innovation announced an investment and partnership with Coracoid Solutions (CCS), an early-stage device company focused on sports medicine.
CCS is developing proprietary technology to address challenges inherent in acromioclavicular joint reconstruction.
Used in combination to repair disruption of the acromioclavicular/coracoclavicular ligaments, the products have clinically demonstrated an easy, safe and biomechanically sound reconstruction method. A minimally invasive, single-use device, the J-Passâ„¢ allows safe passage under the coracoid and clavicle, while the M-Fixâ„¢ provides a wide prosthetic weave with a low-profile locking buckle. M-Fix can be incorporated with clavicular plating or used alone.
CCS is preparing for limited commercialization of its FDA 510(k)-cleared products. The platform will be further developed for other applications through the Parvizi/CCS partnership, including cerclage and soft tissue fixation.
Parvizi Surgical Innovation announced an investment and partnership with Coracoid Solutions (CCS), an early-stage device company focused on sports medicine.
CCS is developing proprietary technology to address challenges inherent in acromioclavicular joint reconstruction.
Used in combination to repair disruption of the...
Parvizi Surgical Innovation announced an investment and partnership with Coracoid Solutions (CCS), an early-stage device company focused on sports medicine.
CCS is developing proprietary technology to address challenges inherent in acromioclavicular joint reconstruction.
Used in combination to repair disruption of the acromioclavicular/coracoclavicular ligaments, the products have clinically demonstrated an easy, safe and biomechanically sound reconstruction method. A minimally invasive, single-use device, the J-Passâ„¢ allows safe passage under the coracoid and clavicle, while the M-Fixâ„¢ provides a wide prosthetic weave with a low-profile locking buckle. M-Fix can be incorporated with clavicular plating or used alone.
CCS is preparing for limited commercialization of its FDA 510(k)-cleared products. The platform will be further developed for other applications through the Parvizi/CCS partnership, including cerclage and soft tissue fixation.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
